Episomal vectors are promising tools in the field of both transgenesis and gene therapy applications. pEPI-1 and its derived vectors rely on S/MAR (Scaffold/Matrix attachment region) sequences to be episomally retained within an eukaryotic nucleus without the need for viral trans-acting factors. This system has been successfully used both in vitro and in vivo, but in the latter case only somatic gene delivery and transgenic foetuses (Manzini et al. PNAS 2006) have been reported so far. To further investigate pEPI in a fully developed animal, we constructed pEPI vectors encoding for three human genes (HMOX1, ENTPD1 and NT5E) and tested them in an in vitro blastocysts production system combined to Sperm Mediated Gene Transfer (SMGT) using all three vectors simultaneously. A total of 403 genetically modified blastocysts were produced using DNA-treated spermatozoa and analyzed with multiplexed PCR. 23% of the blastocysts were triple transgenic, 18% double transgenic, 33% single transgenic and 26% non transgenic. The non-viral episomal constructs were then used in SMGT experiments to produce multi-gene transgenic pigs. 27 live piglets in 3 deliveries were obtained and biopsies analyzed for the presence of transgenic DNA. 7 pigs were non transgenic, 9 single transgenic, 8 double transgenic and 1 pig was triple transgenic. Although at birth the transgenic piglets expressed the transgenes at RNA levels, at month 5, the RNA expression (assayed by QRT–PCR) lowered to a very low to undetectable levels in most of the transgenic pigs (muscle and skin biopsies). 10 month-old pigs were sacrificed and the genetic and expression analyses on different organs revealed that the pEPI vectors were not efficiently expressing the human genes and that they were diluted at very low copy number.Recently it has been shown that the IE-CMV promoter of pEPI is progressively silenced both in vitro and in vivo by hydrodynamic injection in a model of regenerating liver in mouse. It has also been demonstrated that pEPI episomal maintenance relies on an active transcription through the S/MAR sequence. We hypothesize that the progressive silencing of IE-CMV promoter led to vector loss in porcine cells and tissues, thus suggesting the decline in pigs positive for human genes at both DNA and RNA levels. We substituted IE-CMV promoter with CAGGS cassette, containing a hybrid CMVchicken beta actin promoter, which is reportedly not prone to silencing. This work was supported by EU grant LSHB-CT-2006-037377

Giovannoni, R., Vargiolu, A., Manzini, S., De Cecco, M., Seruggia, D., Busnelli, M., et al. (2010). CMV-based episomal vector is progressively lost in vivo in multi-gene transgenic pigs produced by SMGT. In Program and Abstracts of the 9th Transgenic Technology Meeting (TT2010) (pp.330-330). Springer [10.1007/s11248-010-9366-9].

CMV-based episomal vector is progressively lost in vivo in multi-gene transgenic pigs produced by SMGT

GIOVANNONI, ROBERTO;VARGIOLU, ALESSIA;MANZINI, STEFANO;BUSNELLI, MARCO;CERRITO, MARIA GRAZIA;LAVITRANO, MARIALUISA
2010

Abstract

Episomal vectors are promising tools in the field of both transgenesis and gene therapy applications. pEPI-1 and its derived vectors rely on S/MAR (Scaffold/Matrix attachment region) sequences to be episomally retained within an eukaryotic nucleus without the need for viral trans-acting factors. This system has been successfully used both in vitro and in vivo, but in the latter case only somatic gene delivery and transgenic foetuses (Manzini et al. PNAS 2006) have been reported so far. To further investigate pEPI in a fully developed animal, we constructed pEPI vectors encoding for three human genes (HMOX1, ENTPD1 and NT5E) and tested them in an in vitro blastocysts production system combined to Sperm Mediated Gene Transfer (SMGT) using all three vectors simultaneously. A total of 403 genetically modified blastocysts were produced using DNA-treated spermatozoa and analyzed with multiplexed PCR. 23% of the blastocysts were triple transgenic, 18% double transgenic, 33% single transgenic and 26% non transgenic. The non-viral episomal constructs were then used in SMGT experiments to produce multi-gene transgenic pigs. 27 live piglets in 3 deliveries were obtained and biopsies analyzed for the presence of transgenic DNA. 7 pigs were non transgenic, 9 single transgenic, 8 double transgenic and 1 pig was triple transgenic. Although at birth the transgenic piglets expressed the transgenes at RNA levels, at month 5, the RNA expression (assayed by QRT–PCR) lowered to a very low to undetectable levels in most of the transgenic pigs (muscle and skin biopsies). 10 month-old pigs were sacrificed and the genetic and expression analyses on different organs revealed that the pEPI vectors were not efficiently expressing the human genes and that they were diluted at very low copy number.Recently it has been shown that the IE-CMV promoter of pEPI is progressively silenced both in vitro and in vivo by hydrodynamic injection in a model of regenerating liver in mouse. It has also been demonstrated that pEPI episomal maintenance relies on an active transcription through the S/MAR sequence. We hypothesize that the progressive silencing of IE-CMV promoter led to vector loss in porcine cells and tissues, thus suggesting the decline in pigs positive for human genes at both DNA and RNA levels. We substituted IE-CMV promoter with CAGGS cassette, containing a hybrid CMVchicken beta actin promoter, which is reportedly not prone to silencing. This work was supported by EU grant LSHB-CT-2006-037377
abstract + poster
Transgenesis; Animal Model; episomal vector
English
9th Transgenic Technology Meeting (TT2010)
2010
Program and Abstracts of the 9th Transgenic Technology Meeting (TT2010)
2010
19
2
330
330
open
Giovannoni, R., Vargiolu, A., Manzini, S., De Cecco, M., Seruggia, D., Busnelli, M., et al. (2010). CMV-based episomal vector is progressively lost in vivo in multi-gene transgenic pigs produced by SMGT. In Program and Abstracts of the 9th Transgenic Technology Meeting (TT2010) (pp.330-330). Springer [10.1007/s11248-010-9366-9].
File in questo prodotto:
File Dimensione Formato  
Giovannoni-2010-Transgenic Res-AAM.pdf

accesso aperto

Descrizione: Intervento a convegno - abstract
Tipologia di allegato: Author’s Accepted Manuscript, AAM (Post-print)
Licenza: Altro
Dimensione 68.46 kB
Formato Adobe PDF
68.46 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/10819
Citazioni
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 5
Social impact